Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers
Abstract Background Central nervous system (CNS) spreading from epithelial ovarian carcinoma (EOC) is an uncommon but increasing phenomenon. We previously reported in a small series of 11 patients a correlation between Androgen Receptor (AR) loss and localization to CNS. Aims of this study were: to...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-05-01
|
| Series: | Journal of Ovarian Research |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13048-020-00655-2 |
| _version_ | 1828081488679141376 |
|---|---|
| author | Gloria Mittica Margherita Goia Angela Gambino Giulia Scotto Mattia Fonte Rebecca Senetta Massimo Aglietta Fulvio Borella Anna Sapino Dionyssios Katsaros Furio Maggiorotto Eleonora Ghisoni Gaia Giannone Valentina Tuninetti Sofia Genta Chiara Eusebi Marina Momi Paola Cassoni Giorgio Valabrega |
| author_facet | Gloria Mittica Margherita Goia Angela Gambino Giulia Scotto Mattia Fonte Rebecca Senetta Massimo Aglietta Fulvio Borella Anna Sapino Dionyssios Katsaros Furio Maggiorotto Eleonora Ghisoni Gaia Giannone Valentina Tuninetti Sofia Genta Chiara Eusebi Marina Momi Paola Cassoni Giorgio Valabrega |
| author_sort | Gloria Mittica |
| collection | DOAJ |
| description | Abstract Background Central nervous system (CNS) spreading from epithelial ovarian carcinoma (EOC) is an uncommon but increasing phenomenon. We previously reported in a small series of 11 patients a correlation between Androgen Receptor (AR) loss and localization to CNS. Aims of this study were: to confirm a predictive role of AR loss in an independent validation cohort; to evaluate if AR status impacts on EOC survival. Results We collected an additional 29 cases and 19 controls as validation cohort. In this independent cohort at univariate analysis, cases exhibited lower expression of AR, considered both as continuous (p < 0.001) and as discrete variable (10% cut-off: p < 0.003; Immunoreactive score: p < 0.001). AR negative EOC showed an odds ratio (OR) = 8.33 for CNS dissemination compared with AR positive EOC. Kaplan-Meier curves of the combined dataset, combining data of new validation cohort with the previously published cohort, showed that AR < 10% significantly correlates with worse outcomes (p = 0.005 for Progression Free Survival (PFS) and p = 0.002 for brain PFS (bPFS) respectively). Comparison of AR expression between primary tissue and paired brain metastases in the combined dataset did not show any statistically significant difference. Conclusions We confirmed AR loss as predictive role for CNS involvement from EOC in an independent cohort of cases and controls. Early assessment of AR status could improve clinical management and patients’ prognosis. |
| first_indexed | 2024-04-11T03:35:44Z |
| format | Article |
| id | doaj.art-90a412445b4f442b9c28c61a06a3d2a9 |
| institution | Directory Open Access Journal |
| issn | 1757-2215 |
| language | English |
| last_indexed | 2024-04-11T03:35:44Z |
| publishDate | 2020-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Ovarian Research |
| spelling | doaj.art-90a412445b4f442b9c28c61a06a3d2a92023-01-02T05:18:03ZengBMCJournal of Ovarian Research1757-22152020-05-0113111110.1186/s13048-020-00655-2Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancersGloria Mittica0Margherita Goia1Angela Gambino2Giulia Scotto3Mattia Fonte4Rebecca Senetta5Massimo Aglietta6Fulvio Borella7Anna Sapino8Dionyssios Katsaros9Furio Maggiorotto10Eleonora Ghisoni11Gaia Giannone12Valentina Tuninetti13Sofia Genta14Chiara Eusebi15Marina Momi16Paola Cassoni17Giorgio Valabrega18Unit of Oncology, ASL Verbano Cusio Ossola (VCO)Unit of Pathology, Città della Salute e della ScienzaDepartment Obstetrics and Gynecology, University of BresciaDepartment of Oncology, University of TorinoDepartment of Oncology, University of TorinoUnit of Pathology, Città della Salute e della ScienzaDepartment of Oncology, University of TorinoDepartment of Surgical Sciences, Gynecology, AOU, Città della Salute e della ScienzaDepartment of Medical Sciences, University of TurinDepartment of Surgical Sciences, Gynecology, AOU, Città della Salute e della ScienzaCandiolo Cancer Institute, FPO - IRCCSDepartment of Oncology, University of TorinoDepartment of Oncology, University of TorinoDepartment of Oncology, University of TorinoDepartment of Oncology, University of TorinoDepartment Obstetrics and Gynecology, University of BresciaDepartment Obstetrics and Gynecology, University of BresciaUnit of Pathology, Città della Salute e della ScienzaDepartment of Oncology, University of TorinoAbstract Background Central nervous system (CNS) spreading from epithelial ovarian carcinoma (EOC) is an uncommon but increasing phenomenon. We previously reported in a small series of 11 patients a correlation between Androgen Receptor (AR) loss and localization to CNS. Aims of this study were: to confirm a predictive role of AR loss in an independent validation cohort; to evaluate if AR status impacts on EOC survival. Results We collected an additional 29 cases and 19 controls as validation cohort. In this independent cohort at univariate analysis, cases exhibited lower expression of AR, considered both as continuous (p < 0.001) and as discrete variable (10% cut-off: p < 0.003; Immunoreactive score: p < 0.001). AR negative EOC showed an odds ratio (OR) = 8.33 for CNS dissemination compared with AR positive EOC. Kaplan-Meier curves of the combined dataset, combining data of new validation cohort with the previously published cohort, showed that AR < 10% significantly correlates with worse outcomes (p = 0.005 for Progression Free Survival (PFS) and p = 0.002 for brain PFS (bPFS) respectively). Comparison of AR expression between primary tissue and paired brain metastases in the combined dataset did not show any statistically significant difference. Conclusions We confirmed AR loss as predictive role for CNS involvement from EOC in an independent cohort of cases and controls. Early assessment of AR status could improve clinical management and patients’ prognosis.http://link.springer.com/article/10.1186/s13048-020-00655-2Ovarian cancerBrain metastasesAndrogen receptorImmunohistochemistry |
| spellingShingle | Gloria Mittica Margherita Goia Angela Gambino Giulia Scotto Mattia Fonte Rebecca Senetta Massimo Aglietta Fulvio Borella Anna Sapino Dionyssios Katsaros Furio Maggiorotto Eleonora Ghisoni Gaia Giannone Valentina Tuninetti Sofia Genta Chiara Eusebi Marina Momi Paola Cassoni Giorgio Valabrega Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers Journal of Ovarian Research Ovarian cancer Brain metastases Androgen receptor Immunohistochemistry |
| title | Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers |
| title_full | Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers |
| title_fullStr | Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers |
| title_full_unstemmed | Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers |
| title_short | Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers |
| title_sort | validation of androgen receptor loss as a risk factor for the development of brain metastases from ovarian cancers |
| topic | Ovarian cancer Brain metastases Androgen receptor Immunohistochemistry |
| url | http://link.springer.com/article/10.1186/s13048-020-00655-2 |
| work_keys_str_mv | AT gloriamittica validationofandrogenreceptorlossasariskfactorforthedevelopmentofbrainmetastasesfromovariancancers AT margheritagoia validationofandrogenreceptorlossasariskfactorforthedevelopmentofbrainmetastasesfromovariancancers AT angelagambino validationofandrogenreceptorlossasariskfactorforthedevelopmentofbrainmetastasesfromovariancancers AT giuliascotto validationofandrogenreceptorlossasariskfactorforthedevelopmentofbrainmetastasesfromovariancancers AT mattiafonte validationofandrogenreceptorlossasariskfactorforthedevelopmentofbrainmetastasesfromovariancancers AT rebeccasenetta validationofandrogenreceptorlossasariskfactorforthedevelopmentofbrainmetastasesfromovariancancers AT massimoaglietta validationofandrogenreceptorlossasariskfactorforthedevelopmentofbrainmetastasesfromovariancancers AT fulvioborella validationofandrogenreceptorlossasariskfactorforthedevelopmentofbrainmetastasesfromovariancancers AT annasapino validationofandrogenreceptorlossasariskfactorforthedevelopmentofbrainmetastasesfromovariancancers AT dionyssioskatsaros validationofandrogenreceptorlossasariskfactorforthedevelopmentofbrainmetastasesfromovariancancers AT furiomaggiorotto validationofandrogenreceptorlossasariskfactorforthedevelopmentofbrainmetastasesfromovariancancers AT eleonoraghisoni validationofandrogenreceptorlossasariskfactorforthedevelopmentofbrainmetastasesfromovariancancers AT gaiagiannone validationofandrogenreceptorlossasariskfactorforthedevelopmentofbrainmetastasesfromovariancancers AT valentinatuninetti validationofandrogenreceptorlossasariskfactorforthedevelopmentofbrainmetastasesfromovariancancers AT sofiagenta validationofandrogenreceptorlossasariskfactorforthedevelopmentofbrainmetastasesfromovariancancers AT chiaraeusebi validationofandrogenreceptorlossasariskfactorforthedevelopmentofbrainmetastasesfromovariancancers AT marinamomi validationofandrogenreceptorlossasariskfactorforthedevelopmentofbrainmetastasesfromovariancancers AT paolacassoni validationofandrogenreceptorlossasariskfactorforthedevelopmentofbrainmetastasesfromovariancancers AT giorgiovalabrega validationofandrogenreceptorlossasariskfactorforthedevelopmentofbrainmetastasesfromovariancancers |